Related by context. Frequent words. (Click for all words.) 74 Initiates Phase II 74 Enrolls First 74 Receives Orphan Drug Designation 73 Inc Therapeutic Competitors 72 Completes Enrollment 71 Presents Positive 71 Inc. NASDAQ MBLX 71 Inc. Nasdaq IMGN 71 Announces FDA Clearance 71 Advancing Drugs 70 Welcomes Analyst Initiation 70 FDA Clears 70 Therapeutic Competitors 69 fibrosis IPF 69 Commences Phase 69 topical non steroidal 69 CHEAP ONLINE PHARMACY LOW 69 Files Shelf Registration Statement 69 Meets Primary Endpoint 69 R sorafenib tablets 69 system vaporizes unformulated 69 Signs License Agreement 69 DRRX 68 Attracting Bullish Investors 68 WHICH ARE NOT PURELY 68 G GLASS 68 developing Zerenex TM 68 Colorado Coagulation Endocrine Sciences 68 Receives FDA Clearance 68 ® bortezomib 68 Potassium Chloride Sodium Ascorbate 68 Earnings Postmortem 68 phenylketonuria PKU developed 68 CONTAINS FORWARD LOOKING STATEMENTS 68 please visit http:/www.supergen.com 68 Lipid Polymer Micelle LPM 68 Sodium Sulfate Sodium Chloride 68 Kuvan R 68 Announces Initiation 68 ® Duracell 68 Zone TM EncryptAir 68 Takeda Kyowa Hakko Kirin 67 addressing idiopathic pulmonary 67 produces Chrysler Jeep 67 Transdel Pharmaceuticals Inc. 67 SEE CONTINUED UPWARD MOMENTUM 67 MATERIALLY FROM ANY FUTURE 67 Jumps Higher 67 www.combinatorx.com 67 2 methoxyestradiol 67 PINNACLEDIGEST.COM S PAST PERFORMANCE 67 www.vivus.com 67 SEE CONTINUED DOWNWARD MOMENTUM 67 Transcept Pharmaceuticals 67 BY JENNIFER BAKER 67 Q1 Loss Narrows 67 Report companiesandmarkets.com adds 67 Topical Solution 67 READ THE PROXY 67 AS ESTIMATE ANTICIPATE BELIEVE 67 SHIPPED THOUGH THE 67 Ariba logo AribaLIVE 67 Copegus R 67 PRICE GREAT DISCOUNT FREE 67 SHALL NOT BE LIABLE 67 Medarex logo 67 By Neil Osterweil 67 aesthetic medicine BioLook 67 WILL NOT BE REFUNDED 67 Initiates Phase 67 RELEASES ITS QUARTERLY NUMBERS 67 Inc. NASDAQ QLTI 67 topical anti infective 67 Q3 Loss Narrows 66 ANY RESPONSIBILITY FOR ANY 66 Inc. Nasdaq ELGX 66 ACTUAL RESULTS COULD DIFFER 66 CHEAP ONLINE PHARMACY BEST 66 Note SHIPPING CHARGES 66 COMPANIES FUTURE CAPITAL REQUIREMENTS 66 Back Guar 66 Provides Shareholder 66 unter www.ad hoc news.de 66 visit www.PAREXEL.com 66 VEGFR2 inhibitor 66 REGULATORY AUTHORITY HAS APPROVED 66 & http:/www.trading-house.net 66 * Azixa 66 Microwave Fiber TM 66 Q2 Loss Narrows 66 BY JIM HAND 66 BY MARK FARINELLA 66 IS NOT INDICATIVE OF 66 Q2 Loss Widens 66 SEES CONTINUED UPWARD MOMENTUM 66 Calls Purchased 66 NASDAQ CRXL 66 IN ANY TRANSCRIPT 66 BY MICHAEL GELBWASSER 66 gets USFDA nod 66 OR SIMILAR STATEMENTS ARE